$303 Million is the total value of RTW INVESTMENTS, LP's 29 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 79.2% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ACHN | Sell | Achillion Pharmaceuticals Inc | $21,460,000 | +19.9% | 1,988,914 | -23.2% | 7.09% | +27.5% |
BCRX | Sell | BioCryst Pharmaceuticals Inc | $20,748,000 | -18.3% | 2,010,501 | -9.8% | 6.85% | -13.2% |
MRTX | Sell | Mirati Therapeutics Inc | $12,180,000 | -26.6% | 385,456 | -20.0% | 4.02% | -22.0% |
FPRX | Sell | Five Prime Therapeutics Inc | $10,675,000 | -2.8% | 257,236 | -64.0% | 3.53% | +3.3% |
CLDX | Sell | Celldex Therapeutics Inc | $9,992,000 | +31.9% | 637,238 | -11.3% | 3.30% | +40.2% |
Exit | Berkshire Hathaway Inccl b new | $0 | – | -50 | -100.0% | -0.00% | – | |
VCYT | Exit | Veracyte Inc | $0 | – | -25,000 | -100.0% | -0.04% | – |
ELGX | Exit | Endologix Inc | $0 | – | -15,000 | -100.0% | -0.06% | – |
GHDX | Exit | Genomic Health Inc | $0 | – | -15,000 | -100.0% | -0.10% | – |
NTRA | Exit | Natera Inc | $0 | – | -31,693 | -100.0% | -0.11% | – |
BCRX | Exit | BCRX 12/18/2015 CALL 12call | $0 | – | -2,000 | -100.0% | -0.13% | – |
MDRX | Exit | Allscripts Healthcare Solutions Inc | $0 | – | -48,000 | -100.0% | -0.18% | – |
MASI | Exit | Masimo Corp | $0 | – | -25,900 | -100.0% | -0.31% | – |
NLNK | Exit | NewLink Genetics Corp | $0 | – | -28,291 | -100.0% | -0.32% | – |
OSUR | Exit | OraSure Technologies Inc | $0 | – | -322,996 | -100.0% | -0.45% | – |
VBIV | Exit | Vbi Vaccines Inc | $0 | – | -650,000 | -100.0% | -0.53% | – |
RPRX | Exit | Repros Therapeutics Inc | $0 | – | -232,830 | -100.0% | -0.54% | – |
CBIO | Exit | Catalyst Biosciences Inc | $0 | – | -380,806 | -100.0% | -0.55% | – |
LENS | Exit | Presbia Plc | $0 | – | -350,000 | -100.0% | -0.60% | – |
BMY | Exit | BMY 01/15/2016 CALL 60call | $0 | – | -7,500 | -100.0% | -0.80% | – |
Exit | Atara Biotherapeutics Inc. | $0 | – | -262,995 | -100.0% | -2.57% | – | |
Exit | Arrowhead Research Corp | $0 | – | -2,097,185 | -100.0% | -3.75% | – | |
BLUE | Exit | bluebird bio Inc | $0 | – | -151,594 | -100.0% | -4.03% | – |
INCY | Exit | Incyte Corp | $0 | – | -303,212 | -100.0% | -10.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-24
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
MASIMO CORP | 32 | Q3 2023 | 5.8% |
LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
REGENXBIO INC | 30 | Q4 2022 | 10.8% |
AGENUS INC | 29 | Q2 2022 | 9.0% |
PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
ARGENX SE | 26 | Q3 2023 | 5.3% |
VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13D/A | 2024-04-17 |
SC 13D/A | 2024-03-01 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.